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Abstract
Calgranulin genes (S100A8, S100A9 and S100A12) play key immune response roles in
inflammatory disorders, including cardiovascular disease. Long-chain omega-3 polyunsatu-
rated fatty acids (LC n-3 PUFA) may have systemic and adipose tissue-specific anti-inflam-
matory and cardio-protective action. Interactions between calgranulins and the unsaturated
fatty acid arachidonic acid (AA) have been reported, yet little is known about the relationship
between calgranulins and the LC n-3 PUFA eicosapentaenoic acid (EPA) and docosahexa-
enoic acid (DHA). We explored tissue-specific action of calgranulins in the setting of evoked
endotoxemia and n-3 PUFA supplementation. Expression of calgranulins in adipose tissue
in vivo was assessed by RNA sequencing (RNASeq) before and after n-3 PUFA supplemen-
tation and evoked endotoxemia in the fenofibrate and omega-3 fatty acid modulation of
endotoxemia (FFAME) Study. Subjects received n-3 PUFA (n = 8; 3600mg/day EPA/DHA)
or matched placebo (n = 6) for 6–8 weeks, before completing an endotoxin challenge (LPS
0.6 ng/kg). Calgranulin genes were up-regulated post-LPS, with greater increase in n-3
PUFA (S100A8 15-fold, p = 0.003; S100A9 7-fold, p = 0.003; S100A12 28-fold, p = 0.01)
compared to placebo (S100A8 2-fold, p = 0.01; S100A9 1.4-fold, p = 0.4; S100A12 5-fold,
p = 0.06). In an independent evoked endotoxemia study, calgranulin gene expression corre-
lated with the systemic inflammatory response. Through in vivo and in vitro interrogation we
highlight differential responses in adipocytes and mononuclear cells during inflammation,
with n-3 PUFA leading to increased calgranulin expression in adipose, but decreased
expression in circulating cells. In conclusion, we present a novel relationship between n-3
PUFA anti-inflammatory action in vivo and cell-specific modulation of calgranulin expression
during innate immune activation.
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Introduction
Calgranulin genes, which include S100A8, S100A9 and S100A12, are members of the S100
gene family of calcium binding proteins. These proteins have known functions in immune
response, and act as damage-associated molecular pattern (DAMP) proteins, signaling
through the receptor for advanced glycation end products (RAGE), and acting as endogenous
toll-like receptor 4 (TLR4) ligands.[1, 2] These genes are particularly abundant in myeloid
cells, with high protein levels within the cytoplasm of neutrophils and monocytes.[3] S100A12
preferentially forms a homodimer,[4] and may form a tetramer or hexamer,[5] while S100A8
and S100A9 (also known as MRP8 and MRP14) form calprotectin, present as a heterodimer or
heterotetramer; [6, 7] S100A8 and S100A9may also form homodimers and other higher
complexes, subject to post-translational modification[8], with distinct functionality from
calprotectin.
The specific function and disease relevance of calgranulin genes is complex. Expression
and protein levels are increased during immune activation and inflammation, in diverse dis-
ease settings including diabetes, obesity, cardiovascular disease, arthritis, cancer, pancreatitis,
psoriasis, inflammatory bowel disease, and pathogenic infection.[9–14] Serum S100A12 asso-
ciates with risk of CAD in subjects with T2DM.[15] However, whether calgranulins play a
significant regulatory role in disease or are useful as cardiovascular disease markers is not yet
clear.[9, 16] S100A8 and A9 recruit macrophages to adipose tissue from bone marrow mye-
loid progenitors during inflammation and in the setting of hyperglycemia and obesity,[17–
19] and may regulate inflammation through inflammasome activation.[20] S100A8 and A9
are thought to have both pro- and anti-inflammatory action, acting in a cell-type specific
manner[21], with potential importance in the resolution of inflammation.[22, 23] They have
distinct intracellular and extracellular functions, potentially mediated by differences in Ca2+
concentrations within the cell compared with the extracellular environment, and may exert
anti-microbial action through sequestration of metal ions, thus depriving pathogens of essen-
tial nutrients.[13] As a heterodimer, but not as individual subunits, S100A8/A9 may function
as a fatty acid carrier in neutrophils by forming a complex with selected fatty acids, preferen-
tially binding unsaturated fatty acids.[24, 25] S100A8/A9 preferentially binds endothelial
cells in vitro in the presence of the n-6 polyunsaturated fatty acid arachidonic acid when com-
pared with saturated and monounsaturated fatty acids.[26] S100A8/A9 stability has been
reported to be altered in the presence of unsaturated fatty acids, and thus the specific fatty
acid milieu may alter S100A8/A9 functionality during inflammation.[27] However, to our
knowledge, calgranulin modulation and interaction with long-chain n-3 PUFA has not been
studied.
We examined calgranulin gene expression in adipose tissue after n-3 PUFA supplemen-
tation and in vivo lipopolysaccharide (LPS) challenge in the Fenofibrate and omega-3
fatty acid modulation of endotoxemia (FFAME) Study.[28] We found significant up-
regulation of S100A8, S100A9 and S100A12 in response to LPS in vivo, with evidence of
markedly enhanced induction in the setting of high-dose (3600mg/day EPA/DHA) supple-
mental n-3 PUFA. In an independent human endotoxemia study (GENE), we found a tis-
sue-specific relationship between calgranulin expression and the systemic inflammatory
response, with higher adipose tissue expression associated with lower systemic inflamma-
tion, while higher expression in circulating mononuclear cells is associated with increased
systemic inflammation. Finally, we provide integrative genomic and in vitro evidence for
these genes as cell-specific, novel nutrient-dependent regulators of inflammatory
responsiveness.
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Materials and Methods
The FFAME Study
As described,[28] the FFAME Study (clinicaltrials.gov, NCT01048502) recruited healthy vol-
unteers (N = 60, 43% Female, 65% European ancestry [EA], 20% African ancestry [AA], 15%
Asian ancestry) to the University of Pennsylvania (UPenn) for a placebo-controlled (corn oil
(99.4%) with α-tocopherol (0.6%) as an antioxidant). 6–8 week n-3 PUFA supplementation
trial (EPA/DHA at 900mg/day or 3600mg/day) followed by an inpatient evoked endotoxemia
protocol (0.6ng/kg LPS). Samples of gluteal subcutaneous adipose tissue were obtained and
snap-frozen for subsequent RNA extraction. A subset of EA subjects (n = 6 placebo, n = 8 n-3
PUFA 3600mg/day; 50% Female) were selected for adipose tissue RNA sequencing (RNASeq)
of adipose biopsies obtained at baseline, after supplementation, and after LPS challenge (4hrs
post-LPS)[29]. The trial was conducted with the approval of the UPenn Institutional Review
Board, and all participants provided written informed consent.
The GENE Study
The GENE Study recruited healthy individuals (N = 294, 52% Female, 65% EA, 35% AA)
ancestry to a University of Pennsylvania (UPenn) inpatient Clinical and Translational
Research Center (CTRC) protocol as previously described (clinicaltrials.gov NCT00953667).
[30] Participants completed an endotoxin challenge (1ng/kg E coli-derived LPS; U.S. standard
reference, lot No. CCRE-LOT-1+2, Clinical Center, Pharmacy Department at the National
Institutes of Health, Bethesda MD).[30, 31] Multiple clinical variables were assessed during the
visit. Individuals were ranked by their peak clinical inflammatory response (Δ from baseline
for fever, plasma TNFα, plasma IL-6). Individuals falling within the top and bottom 5% of
responses were designated as “high” or “low” responders respectively. CD14+ monocytes were
isolated from whole blood using magnetic bead selection (Dynabeads1 CD14, ThermoFisher,
Waltham MA), and frozen in TRIzol reagent (ThermoFisher, Waltham MA) for subsequent
RNA extraction via standard protocol.[32]. The GENE study was approved by UPenn’s Insti-
tutional Review Board (IRB), with regulatory oversight by the FDA (LPS: IND# 5984) and an
NIH-appointed data-safety and monitoring board. All subjects provided written informed
consent.
Laboratory Methods
RNA extraction and expression analysis. RNA from FFAME Study adipose tissue biop-
sies (3 samples per subject) was extracted using the RNeasy total RNA kit (Qiagen Inc, Valen-
cia, CA).[33] RNA concentration and quality was assessed using an Agilent BioAnalyzer
(Agilent, Santa Clara, CA). Strand-specific poly-A RNA libraries (TruSeq RNA Sample Prepa-
ration Kit, Illumina, San Diego, CA) were prepared as described.[32] Briefly, libraries were
sequenced on an Illumina HiSeq 2000 sequencer, with 6 samples per lane (~30million 2×101
bp paired-end reads per sample after filtering). RNASeq data were generated and analyzed for
the GENE Study as described.[32] For the in vitro experiments, RNA was subjected to
RT-PCR and subsequent quantitative PCR (qPCR) using pre-designed primers and probes
(Applied Biosystems 7900 Real-Time PCR System, Foster City, CA) for measurement of candi-
date gene mRNA (S100A8, S100A9, S100A12). Gene expression levels were normalized to
GAPDH and analyzed using the relative quantitation 2-(ΔΔCt) method to determine relative-
change.
Plasma protein analysis. Blood samples were collected into EDTA tubes, mixed by inver-
sion, and immediately placed on ice. Plasma was obtained through centrifugation, and
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immediately frozen and stored at -80˚C for subsequent analysis. Plasma S100A9 protein was
measured in a subset of individuals from the GENE study before and after LPS (n = 16) using
the SOMALogic SOMAscan assay.[34] This assay panel measures 1129 proteins simulta-
neously using aptamer technology.
Cell culture experiments. For in vitro experiments, pre-adipocytes from the stromal vas-
cular fraction (SVF) were isolated, cultured and differentiated to adipocytes as previously
described.[35] Briefly, cells were grown to confluence in OF medium with 20% fetal bovine
serum and differentiated in serum-free medium with high insulin and PPARγ agonist.[35, 36]
Adipocytes were treated with EPA and DHA (50μM in dimethyl sulfoxide [DMSO]; Sigma-
Aldrich, St. Louis, MO) or vehicle (DMSO) for 48 hours. THP-1 monocytes (Sigma-Aldrich,
St. Louis, MO) were treated with EPA and DHA (100 μM in DMSO) or vehicle (DMSO) for 72
hours. Treatment concentration and time for each cell type was determined based on previous
time and dose response experiments (data not shown). Cells were then treated with LPS
(100ng/ml) for 4 hours, and harvested for RNA extraction using Trizol reagent (Life Technolo-
gies, Foster City, CA).
Macrophage differentiation and polarization. As described[37], peripheral blood
mononuclear cells (PBMCs) were collected using Mononuclear Cell Preparation tubes (BD
Vacutainer) and cultured for 7 days to induce macrophage differentiation. Macrophages were
polarized using LPS and interferon-γ (M1) or IL-4 (M2)[38]. RNA was extracted (All Prep
DNA/RNA/miRNA Universal Kit; Qiagen, Valencia, CA) and RNASeq libraries were prepared
(TruSeq RNA Sample Preparation Kit; Illumina, San Diego, CA), and sequenced (Illumina
HiSeq 2000) as described[37, 39]. RNASeq data are available from the NCBI Gene Expression
Omnibus under the accession numbers GSE55536.
Statistical Analysis and Bioinformatics
RNASeq data were aligned to the hg19 reference genome using STAR 2.3.0e[40] with default
options. RNA-SeqC[41] was used to assess quality of each sample. Estimated gene expression
levels from pre- to post-LPS were quantified as fragments per kilobase per million fragments
mapped (FPKM), and analyzed using the cuffdiff option in Cufflinks version 2.1.1. Relative
expression fold changes were calculated by dividing post-LPS by pre-LPS expression values.
FFAME Study RNASeq data were deposited to Gene Expression Omnibus (GEO, http://www.
ncbi.nlm.nih.gov/geo/), accession number GSE87426. GENE Study data are deposited under
accession number GSE39118. Publicly available expression data (GSE5099 and GSE28070)
were queried from datasets deposited in GEO and analyzed using GEO2R.[42] In vitro and
protein data were assessed for normality of distribution, and analyzed by 1-way ANOVA,
2-way ANOVA and by Spearman correlation. Data analysis was carried out using IBM SPSS
Statistics 22 and GraphPad Prism 6. All p values quoted for array-wide experiments (e.g. RNA-
Seq, microarray, eQTL) are after adjustment for platform-specific multiple testing.
Results
Expression of S100A8, S100A9 and S100A12 is Increased in Adipose
Tissue in Response to LPS Following n-3 PUFA Supplementation
In the FFAME Study endotoxin challenge, S100A8, S100A9 and S100A12 expression was
increased in adipose tissue post-LPS in both the placebo and the n-3 PUFA group, however
this was markedly enhanced following n-3 PUFA supplementation. Expression levels of
S100A8 and S100A9were higher than that of S100A12 (average pre-LPS FPKM S100A8= 6,
S100A9= 14, S100A12= 0.5). All three calgranulin genes were highly up-regulated post-LPS in
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the n-3 PUFA group (S100A8~15-fold, p = 0.003; S100A9~7-fold, p = 0.003; S100A12
~28-fold, p = 0.01), while they were only moderately increased post-LPS in the placebo group
(S100A8~2-fold, p = 0.01; S100A9~1.4-fold, p = 0.4; S100A12~5-fold, p = 0.06) (Fig 1). This
increased activation in the n-3 PUFA group compared with placebo reached statistical signifi-
cance for S100A9 (p = 0.04). As previously described, individuals in the n-3 PUFA group dis-
played a lower systemic inflammatory response to LPS compared with placebo.[28] There was
no change in calgranulin gene expression from n-3 PUFA vs. placebo supplementation prior
to LPS administration in either the n-3 PUFA or placebo groups, indicating that the effect of
n-3 PUFA on expression of these genes may be dependent on an additional immune stimulus.
Expression of S100A8 and S100A9 is Higher in Adipose Tissue of
Individuals with High Habitual n-3 PUFA Consumption
We hypothesized that this n-3 PUFA and inflammation-dependent difference in calgranulin
expression may be more pronounced in a disease setting. In a cross-sectional study of obese
metabolic syndrome patients (Gene Expression Omnibus (GEO) dataset GSE28070 analyzed
using GEO2R)[43] we observed a significant difference in S100A8 and S100A9 expression in
adipose tissue from individuals with low habitual n-3 PUFA intake (<1g/day, n = 6) vs. high
habitual intake (>2g/day, n = 6). There was ~4-fold higher expression in individuals with n-3
PUFA intake >2g/day compared with those consuming <1g/day (S100A8, logFC = 1.92, adj
p = 0.038; S100A9, logFC = 2.49, p = 0.027) consistent with a role for n-3 PUFA in enhancing
expression in adipose tissue in the chronic inflammatory state of obesity. There were no signif-
icant differences between the groups in other known inflammatory genes, e.g. IL6, IL10,
CX3CL1,CCL2, (all adj. p>0.1, logFC<1) indicating that n-3 PUFA modulated S100A8 and
S100A9 specifically, rather than broadly modifying the overall inflammatory state.
Tissue-specific Calgranulin Expression Response to LPS
Our discovery sample was focused on adipose tissue. However, we hypothesized that there
would also be an increase in gene expression in circulating mononuclear cells post-LPS in vivo.
In an independent human endotoxemia protocol, the GENE Study,[30, 32] which adminis-
tered a higher dose of LPS than the FFAME Study (1ng/kg LPS), we examined expression of
S100A8, S100A9 and S100A12 pre- and post-LPS in adipose tissue (n = 25), and CD14+ mono-
cytes (n = 15) of healthy individuals (n = 11 overlapped both tissues). There was a significant
increase in all three genes in adipose tissue post-LPS: S100A8 (15-fold, p = 0.001), S100A9
(~10-fold, p = 0.001), and S100A12 (~40-fold, p = 0.001). Further, expression of all three genes
was increased significantly 2 hours post-LPS in CD14+ monocytes (S100A8 5-fold, p = 0.01;
S100A9 4-fold, p = 0.01; S100A12 5-fold, p = 0.01). Because these individuals had previously
been chosen for RNASeq based on their extreme phenotypic response to LPS (top and bottom
5% of the distribution for plasma cytokine and systemic febrile response), we examined the
stratified gene expression changes in these “high” or “low” responders to LPS. We hypothe-
sized that calgranulin gene expression in response to LPS would differ in individuals with
strongly divergent clinical responses to LPS. Indeed, in adipose tissue, there was an approxi-
mately 3-fold greater increase in calgranulin gene up-regulation in “low” responders vs. “high”
responders (Fig 2A). This corresponds to the findings in FFAME, where higher adipose
expression in the n-3 PUFA group was associated with lower levels of systemic inflammatory
activation. Conversely, in CD14+ monocytes, this directionality was reversed, with 2-3-fold
higher up-regulation of S100A8, S100A9 and S100A12 in “high” responders compared with
“low” responders. (Fig 2B), suggesting tissue-specific differences in response and function. To
determine whether there was a relationship between calgranulin expression across tissues
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Fig 1. Calgranulin expression S100A8 (A), S100A9 (B) and S100A12 (C) was markedly increased in
adipose tissue following n-3 PUFA supplementation and LPS in FFAME Study participants (n = 6
placebo, n = 8 n-3 PUFA). * indicates p<0.01. Data plotted as mean Fragments per kilobase per million
fragments mapped (FPKM) and standard error.
doi:10.1371/journal.pone.0169614.g001
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Fig 2. Up-regulation of S100A8, S100A9 and S100A12 in adipose tissue and CD14+ monocytes post-
LPS in the GENE Study corresponds to the degree of systemic response to LPS, with a negative
relationship in adipose tissue (A) and a positive relationship in CD14+ monocytes (B). Data plotted as
mean fold change and standard deviation.
doi:10.1371/journal.pone.0169614.g002
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within the same individual, we examined correlations between adipose and CD14+ monocyte
expression in the 11 individuals with expression data in both tissues. As expected, at each time-
point expression of all 3 genes correlated strongly and significantly with each other (e.g. pre-
LPS CD14+ monocyte S100A8 and S100A9, Spearman’s rho = 0.845, p<0.001). In CD14+
monocytes, baseline S100A8 expression was positively correlated with post-LPS S100A8
expression (Spearman’s rho = 0.74, P = 0.01). Strikingly, baseline CD14+ monocyte S100A8
and S100A9 expression was significantly negatively correlated with post-LPS adipose expres-
sion of all 3 genes, e.g. for S100A9 baseline in CD14+ monocytes, the relationship with post-
LPS adipose expression was as follows: S100A8 Spearman’s rho = -0.8, P = 0.003; S100A9
Spearman’s rho = -0.75, P = 0.007; S100A12 Spearman’s rho = -0.67, P = 0.02). Thus, high cal-
granulin expression in circulating cells at baseline may predict low adipose tissue calgranulin
induction during inflammatory stress.
S100A9 Protein is Increased in Plasma Post-LPS
We probed whether the observed tissue increase in gene expression resulted in an increase in
secreted protein levels. While plasma protein could not be measured in the FFAME Study
(due to limited sample for secondary analyses), we measured plasma S100A9 levels in a subset
of the individuals (n = 16) whose adipose and CD14+ monocyte gene expression was mea-
sured in the GENE Study.[30] S100A9 protein in plasma was increased significantly 2 hours
post-LPS (1.8-fold, p = 0.01), and remained elevated 24-hours post-LPS (1.5-fold, p = 0.02).
When stratified into “high” and “low” responders as described above, there was greater post-
LPS increase in plasma S100A9 protein in high responders (n = 8) compared with low
responders (n = 8), p = 0.01 for timegroup interaction (Fig 3). Post-LPS levels of plasma
S100A9 correlated significantly with post-LPS levels of IL-6 (Spearman’s rho = 0.9, P<0.0001),
TNFα (Spearman’s rho = 0.8, P<0.001), and CXCL10 (Spearman’s rho = 0.8, P<0.0001).
Interestingly, baseline levels of S100A9 correlated significantly with baseline CRP (Spearman’s
Fig 3. Plasma S100A9 protein following LPS in high and low systemic responders to evoked
endotoxemia in the GENE Study. There was a significant difference in plasma S100A9 response to LPS
between high and low responders (p = 0.01 for time*group interaction).
doi:10.1371/journal.pone.0169614.g003
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rho = 0.6, P = 0.014). In contrast, plasma levels of IL6, TNFα and CXCL10 do not correlate
with CRP. Thus, plasma S100A9 may be a marker both of acute inflammatory activation, and
of chronic inflammatory stress.
Expression of Calgranulin Genes is Modulated by n-3 PUFA Treatment
and LPS in vitro, with Differential Effects in THP-1 Monocytes Compared
to Adipocytes
To further examine the divergent adipose and monocyte-specific responses, we examined cell-
specific responses of calgranulin expression in vitro to n-3 PUFA and LPS in the THP-1 mono-
cyte cell line and adipocytes. In THP-1 cells, expression of S100A8, S100A9 and S100A12
increased significantly following treatment with EPA + DHA (p<0.001 for S100A8 and
S100A9, p<0.01 for S100A12) (Fig 4). In contrast, in adipocytes, expression of both S100A8
and S100A9 decreased significantly with DHA + EPA treatment (p<0.001). We could not
detect expression of S100A12 in adipocytes, indicating that expression of this gene in adipose
tissue may derive from other adipose cell sources (e.g. endothelial, macrophages, stromal
cells).
In THP-1 cells, S100A9 and S100A12were significantly up-regulated by LPS, while there
was no significant change in S100A8. However, pre-treatment with n-3 PUFA prior to LPS
resulted in significant attenuation of the LPS-induced increase in expression, with significantly
lower expression following EPA+DHA treatment compared with control in all 3 genes (Fig 5).
In adipocytes, while S100A8 and S100A9were not significantly up-regulated by LPS alone,
pre-treatment with EPA+DHA resulted in a significant LPS-induced increase in expression of
both genes, again contrasting with the directionality of the effect in THP-1 cells, and consistent
with the directionality of the in vivo data.
Expression of Calgranulin Genes is Decreased During Maturation of
Monocytes to Macrophages
We queried expression of calgranulins in freshly isolated monocytes and during maturation to
macrophages (GEO data series GSE5099).[44] Expression of S100A8 (LogFC = -4.09,
p = 0.0003), S100A9 (LogFC = -1.77, p = 0.005) and S100A12 (LogFC = -4.85, p = 0.00005)
decreased during maturation of monocytes to mature macrophages. In our own expression
data from primary human macrophages and M1 or M2 polarized macrophages (available at
GEO data series GSE55536),[37] there was a significant decrease in both S100A8 (down
~3-fold, p = 0.004) and S100A9 (down ~10-fold, p = 0.0004) during polarization to M1, and
similarly during polarization to M2: S100A8 down ~5-fold p = 0.005; S100A9 down ~3-fold
p = 0.005, with a greater decrease in S100A9 in M1 compared with M2 (p = 0.0004). There was
no significant change in S100A12 expression in these cells.
Discussion
As important immune-mediating genes, calgranulins are of particular interest to chronic
inflammatory diseases including cardiovascular disease. Dietary n-3 PUFA consumption may
protect against a diverse range of immune-related diseases, although conflicting data on mech-
anisms and outcomes have hindered translational progress. Previous studies have examined
the specific pro- or anti-inflammatory actions of S100A8, S100A9 and S100A12, however to
our knowledge these genes have not been studied for potential interaction with n-3 PUFA. We
present evidence that consumption of n-3 PUFA is associated with enhanced expression of cal-
granulins within adipose tissue in response to an acute inflammatory challenge, as well as in
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the setting of chronic low-grade inflammation. We report novel differences in the response in
adipocytes and adipose tissue compared with circulating mononuclear cells. Through integra-
tion of these data, we hypothesize that calgranulins mediatecell-specific n-3 PUFA-dependent
regulation of systemic inflammation.
There was no difference in adipose calgranulin expression after n-3 PUFA treatment prior
to endotoxemia in the FFAME study, consistent with the expectation that basal tissue inflam-
mation in healthy individuals is at negligible levels. External endotoxemic inflammatory stress
Fig 4. Expression of calgranulin genes (S100A8, S100A9, S100A12) is modulated by n-3 PUFA treatment in human THP-1 cells
and adipocytes. *** indicates p<0.001; ** indicates p<0.01. Data plotted as mean fold change and standard deviation.
doi:10.1371/journal.pone.0169614.g004
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Fig 5. Expression of calgranulin genes (S100A8, S100A9, S100A12) in response to stimulation with LPS is modulated
by n-3 PUFA treatment in human THP-1 cells and adipocytes. *** indicates p<0.001; ** indicates p<0.01; * indicates
p<0.05. Data plotted as mean fold change and standard deviation.
doi:10.1371/journal.pone.0169614.g005
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was required to observe expression differences in this lean and healthy sample. However in
adipose tissue from obese individuals[43] there was higher expression in individuals with
higher habitual intake (>2g/day) compared with low habitual intake (<1g/day). Given that
obesity is associated with increased adipose inflammation,[45] it is possible that the increased
inflammatory milieu in adipose from obese individuals modulates n-3 PUFA-associated differ-
ence, analogous to the evoked inflammatory challenge.
Strikingly, we observed tissue-specific differences in calgranulin gene expression in individ-
uals with high or low systemic inflammatory responses (as assessed by fever and circulating
cytokines). In adipose tissue in vivo, there was greater induction of calgranulins concurrent
with lower systemic inflammatory response. This was observed in the FFAME Study, where
the n-3 PUFA supplemented group had lower febrile and cytokine response to LPS than the
placebo group. Similarly, in the GENE Study, where individuals were designated as “high” or
“low” responders based on their febrile and cytokine response to LPS, the individuals with
“low” response had higher post-LPS up-regulation of calgranulins in adipose tissue. Remark-
ably, within a subset of the same individuals in the GENE Study, “low” responders had lower
post-LPS up-regulation of calgranulins in CD14+ monocytes. This striking difference raised
the possibility of tissue-localization as crucially important in downstream consequences of cal-
granulin gene expression. The tissue-specific difference was recapitulated in vitro, where the
effects of n-3 PUFA alone, as well as n-3 PUFA and LPS had opposing effects in adipocytes
compared with THP-1 monocytes. Our data highlight that n-3 PUFA treatment has different
effects on calgranulin expression in both adipocytes and monocytes when it is used alone,
compared with the combination of n-3 PUFA and LPS. This could indicate that the relation-
ship between n-3 PUFA and calgranulin expression is fundamentally altered during acute
inflammatory stress compared with an unstressed state. Plasma responses of S100A9 protein
were broadly consistent with CD14+ monocyte expression, indicating that plasma S100A9
protein may be primarily derived from secretion by circulating inflammatory cells rather than
from adipose tissue.
Recent reports suggest that that S100A8 and S100A9 are involved in the recruitment of adi-
pose tissue macrophages from bone marrow through a positive feedback loop,[18] and modu-
late leukocyte rolling and adhesion during recruitment.[46] S100A8 and S100A9 lead to
inflammasome activation in a TLR4- and MYD88-dependent manner,[18] and stimulate
CXCL10 production in monocytes and macrophages through TLR4 and NF-κB.[47] In our
data, plasma S100A9 protein correlated significantly with plasma CXCL10 post-LPS (but not
at baseline). In mice, s100a8 adipose expression, as well as S100A8 protein was shown to stim-
ulate macrophage migration as an early mediator of adipose inflammation in response to a
pro-inflammatory obesogenic diet.[17]. In obese subjects, PBMC expression of S100A8,
S100A9 and S100A12 correlated positively with visceral obesity.[48] Our data are consistent
with a model where high circulating calgranulins are associated with increased chronic inflam-
mation. Conversely, high adipose expression may be associated with reduced inflammation.
Indeed, subjects with high baseline expression of calgranulins in CD14+ monocytes had lower
induction of calgranulin expression in adipose tissue post-LPS. In the acute inflammatory set-
ting, our novel findings suggest that the presence of LC n-3 PUFA may facilitate rapid up-reg-
ulation of calgranulin expression in adipose. This may lead to a more rapid resolution of
systemic inflammation, potentially through an increase in macrophage recruitment and
inflammasome activation. While intriguing, the correlative associations in our data do not
demonstrate causality, and the mechanisms remains to be determined in future studies.
Our study has a number of strengths, but also some limitations. Our in vivo adipose tissue
and CD14+ monocyte expression data reflects expression from a mixed cell population. In
vitro expression data indicate higher S100A8, S100A9 and S100A12 expression in monocytes
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compared with mature macrophages, with further decreases during polarization to M1 or M2
macrophages. Thus, observed differences in expression within adipose tissue and in the circu-
lation may relate to the proportion of monocytes compared with activated macrophages,
rather than the number or activity of resident and infiltrating cells. The relative contribution
of macrophage recruitment vs. macrophage activation status remains to be determined. Circu-
lating or adipose tissue protein could not be measured in the FFAME Study due to limited
sample availability, and thus the degree to which gene expression relates to translated protein
could not be verified. However in the GENE Study expression of S100A9 in adipose tissue
post-LPS was significantly correlated with plasma protein. The specific functions of the calgra-
nulin genes and interaction with n-3 PUFA may depend on formation of multimers, as well as
intracellular vs. extracellular localization, which our data do not resolve. Given previous stud-
ies showing direct interaction between calgranulins and fatty acids[24, 25, 27], it is possible
that the n-3 PUFA effects are mediated through direct binding or direct effects on stability of
tertiary structure, however it remains possible that the effects are in fact mediated through
fatty acid metabolites or alterations in membrane composition.
Given the increasing prevalence of complex inflammatory cardiometabolic diseases, strate-
gies aimed at understanding specific mechanisms of disease development, and interaction
with environmental factors, are of particular importance. We used a combined model of n-3
PUFA supplementation and evoked endotoxemia in healthy volunteers to understand the
interplay between nutritional status and inflammatory responses prior to development of car-
diometabolic disease. Through in vivo and in vitro interrogation, we highlight calgranulins
S100A8, S100A9 and S100A12 as n-3 PUFA-dependent regulators of systemic and adipose tis-
sue inflammatory responses, and highlight a potential novel mechanism for n-3 PUFA modu-
lation of inflammation.
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